LOW FREQUENCY GLATIRAMER ACETATE THERAPY
First Claim
1. A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
0 Assignments
0 Petitions
Accused Products
Abstract
A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
-
Citations
20 Claims
- 1. A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.
- 16. A method of increasing the tolerability of GA treatment in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis which comprises reducing the frequency of subcutaneous injections of a pharmaceutical composition comprising a therapeutically effective dose of glatiramer acetate to three times over a period of seven days with at least one day between every injection.
Specification
-
- Resources
-
Current AssigneeTeva Pharmaceutical Industries Limited
-
Original AssigneeTeva Pharmaceutical Industries Limited
-
InventorsKlinger, Ety
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/17.9
-
CPC Class CodesA61K 31/19 Carboxylic acids, e.g. valp...A61K 31/785 Polymers containing nitrogenA61K 38/02 Peptides of undefined numbe...A61K 38/07 TetrapeptidesA61K 38/16 Peptides having more than 2...A61K 9/0019 Injectable compositions; In...A61P 3/10 for hyperglycaemia, e.g. an...
